Daiichi Sankyo Co Ltd (4568):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Daiichi Sankyo Co Ltd (4568) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C11425
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd (4568) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Daiichi Sankyo Co Ltd, Medical Equipment, Deal Details 11
Venture Financing 11
Ambit Biosciences Raises US$7.07 Million In Venture Financing 11
Partnerships 12
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12
Daiichi Sankyo Partners with Nitto Denko 13
Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14
Equity Offering 15
Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15
Debt Offering 16
Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16
Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17
Asset Transactions 18
LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18
Acquisition 19
Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19
Daiichi Sankyo Co Ltd – Key Competitors 21
Daiichi Sankyo Co Ltd – Key Employees 22
Daiichi Sankyo Co Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Joint Venture 27
Recent Developments 28
Strategy And Business Planning 28
Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 28
Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 29
Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 31
Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 32
Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 33
Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 35
Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 37
Corporate Communications 38
May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 38
Feb 21, 2018: Daiichi Sankyo Selected for 2018 Certified Health and Productivity Management Organization (White 500) 39
Feb 02, 2018: Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018 40
Sep 15, 2017: Daiichi Sankyo Listed on the Dow Jones Sustainability Indices World Index 41
Feb 24, 2017: Daiichi Sankyo Appoints New Group Corporate Officers 42
Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 43
Legal and Regulatory 44
Jun 06, 2018: Daiichi Sankyo’s U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 44
Government and Public Interest 45
Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 45
Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 46
Other Significant Developments 47
Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 47
Jun 20, 2017: Daiichi Sankyo Selects Deloitte’s ConvergeHEALTH Safety to Transform and Upgrade Global Drug Safety Platform 48
Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 49
Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Daiichi Sankyo Co Ltd, Medical Equipment, Key Facts, 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Daiichi Sankyo Co Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Daiichi Sankyo Co Ltd, Deals By Market, 2012 to YTD 2018 9
Daiichi Sankyo Co Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Ambit Biosciences Raises US$7.07 Million In Venture Financing 11
National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 12
Daiichi Sankyo Partners with Nitto Denko 13
Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 14
Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 15
Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 16
Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 17
LYNCH Biologics Acquires Rights and Certain Assets of Luitpold Pharma 18
Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 19
Daiichi Sankyo Co Ltd, Key Competitors 21
Daiichi Sankyo Co Ltd, Key Employees 22
Daiichi Sankyo Co Ltd, Subsidiaries 24
Daiichi Sankyo Co Ltd, Joint Venture 27

List of Figures
Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Daiichi Sankyo Co Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Daiichi Sankyo Co Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Daiichi Sankyo Co Ltd (4568):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Life Time Inc:企業の戦略的SWOT分析
    Life Time Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Kuraray Co Ltd (3405):企業の財務・戦略的SWOT分析
    Kuraray Co Ltd (3405) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Millendo Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Millendo Therapeutics Inc (Millendo Therapeutics), formerly Atterocor Inc is a drug development company that develops treatments for endocrine diseases including vasomotor. The company provides development of innovative treatments for orphan endocrine disorders such as adrenocortical carcino …
  • Canadian Utilities Limited:企業の戦略・SWOT・財務分析
    Canadian Utilities Limited - Strategy, SWOT and Corporate Finance Report Summary Canadian Utilities Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ggp Inc:企業の戦略・SWOT・財務分析
    Ggp Inc - Strategy, SWOT and Corporate Finance Report Summary Ggp Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Euro India Fresh Foods, Ltd. (EIFFL):企業の財務・戦略的SWOT分析
    Euro India Fresh Foods, Ltd. (EIFFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Elephant Oil Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Elephant Oil Ltd (Elephant Oil) is an oil and gas company. The company provides services such as exploration and production of oil and natural gas. It provides its exploration services in the underexplored areas of West Africa. Elephant Oil holds interest in a production-sharing contract in …
  • Edmond De Rothschild (Suisse) S.A.
    Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report Summary Edmond De Rothschild (Suisse) S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • KCC Corp (002380):企業の財務・戦略的SWOT分析
    KCC Corp (002380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • IDInvest Partners:企業のM&A・事業提携・投資動向
    IDInvest Partners - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IDInvest Partners Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Kohl’s Corporation (KSS):企業の財務・戦略的SWOT分析
    Kohl's Corporation (KSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Texas Municipal Power Agency:企業の戦略的SWOT分析
    Texas Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Revalesio Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Revalesio Corp (Revalesio) is a developer of novel therapeutics for the treatment of inflammatory diseases. The company conducts research and development activities to develop therapeutics in the areas of respiratory, neuroscience and cardiovascular. Its product pipeline includes drugs targe …
  • Bangladesh Power Development Board-エネルギー分野:企業M&A・提携分析
    Summary Bangladesh Power Development Board (BPDB) is an integrated energy statutory board. It generates electricity through owned power plants and procures electricity from public and private generation companies. The board utilizes gas, coal, hydro, furnace oil, and diesel as fuel source for electr …
  • Argan Inc (AGX):企業の財務・戦略的SWOT分析
    Argan Inc (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Innoviva Inc (INVA):企業の財務・戦略的SWOT分析
    Innoviva Inc (INVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • NPC Co., Ltd.:企業の戦略・SWOT・財務情報
    NPC Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary NPC Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Euronet Worldwide, Inc.:企業の戦略・SWOT・財務分析
    Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Euronet Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆